Nanalysis Announces First Quarter 2025 Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 28 2025
0mins
Source: PRnewswire
Financial Performance: Nanalysis Scientific Corp. reported a consolidated revenue of $10,594,000 for Q1 2025, a decrease of 5% from the previous year, but achieved positive Adjusted EBITDA of $180,000, marking an improvement from a loss in the same period last year. The company also improved its product sales gross margin to 66% due to cost reductions and efficiency measures.
Operational Developments: The company is focusing on enhancing operational excellence in its services organization and has made leadership changes to drive growth in its security services segment. Additionally, it launched a new 60 MHz Benchtop NMR product and renegotiated its term loan facility to improve financial flexibility.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
